Fox Run Management, L.L.C. Bluebird Bio, Inc. Transaction History

Fox Run Management, L.L.C.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$3.14 - $8.22 $73,297 - $191,879	23,343 New	23,343 $74,000
Q3 2022 Nov 07, 2022	BUY	$3.75 - $7.39 $78,525 - $154,746	20,940 New	20,940 $133,000
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $110,669 - $206,766	-9,846 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$18.04 - $22.09 $177,621 - $217,498	9,846 New	9,846 $315,000
Q1 2020 May 08, 2020	SELL	$26.16 - $63.5 $137,732 - $334,327	-5,265 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $127,731 - $167,742	2,720 Added 106.88%	5,265 $462,000
Q3 2019 Oct 15, 2019	BUY	$59.47 - $93.1 $151,351 - $236,939	2,545 New	2,545 $234,000
Q3 2018 Oct 05, 2018	SELL	$88.86 - $117.49 $513,877 - $679,444	-5,783 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$99.64 - $127.59 $576,218 - $737,852	5,783 New	5,783 $908,000
Q4 2017 Jan 18, 2018	SELL	$81.25 - $130.7 $357,500 - $575,080	-4,400 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$57.74 - $91.42 $254,056 - $402,248	4,400	4,400 $604,000

112

61.5M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $485M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.